Recital 29, Commission Regulation (EC) No 1024/2009 of 29 October 2009 on the authorisation and refu…

In forcesince 29 Oct 2009

Following an application from Efamol Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Efalex® on brain development and function (Question No EFSA-Q-2008-318) [The EFSA Journal (2008) 898, pp. 1-2.]. The claim proposed by the applicant was worded as follows: ‘Efalex® may help maintain and support brain development and function’.